ON Holding AG vs Zimmer Biomet Holdings Inc — how do they compare? ON Holding AG trades at $35.01 (market cap $11.38B), while Zimmer Biomet Holdings Inc trades at $89.08 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| ONON | ZBH | |
|---|---|---|
Market Cap | $11.38B | $16.95B |
Volume | 13,732,872 | 2,505,240 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $103.98 |
52-Week Low | $26.76 | $79.58 |
Typical Hold Time | 22 Days | 89 Days |
Enterprise Value | $10.54B | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
ONON trades at $34.79, up 4.73% today, reflecting strong momentum. The stock shows bullish technical signals with support at $33 and resistance at $35. Fundamentally, the company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding expectations. Revenue reached $3.01 billion in 2025, with a net income margin of 12.3%. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, driven by earnings growth, strategic expansion, and strong analyst support. Key risks include competitive pressures and market volatility. Analysts maintain a consensus buy rating with a $42.26 price target, suggesting potential upside from current levels.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →